{"id":753183,"date":"2023-05-01T16:13:33","date_gmt":"2023-05-01T20:13:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"modified":"2023-05-01T16:13:33","modified_gmt":"2023-05-01T20:13:33","slug":"cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","title":{"rendered":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\"> SOUTH SAN FRANCISCO, Calif., May  01, 2023  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on\u00a0Tuesday, May 9, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT.<\/p>\n<p align=\"justify\">Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZbV-is7xQWIp2HUqNgOxQyKbdxm8JNaKhn4Zqug4_wYv7VqKXkA4iDD9M3_1I8GKB0tFJ1DgG1VANqoUj88xDD2-KPnrKlKaU48rNLKFjp3pb5VEvJu53SjP3G7hP7GvBw4T_wpNzGiPtFwlMvGeNpjSJBVyj6-mRDtTjhESC2A=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.cytomx.com\/events-and-presentations<\/a>. Participants may register for the conference call <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kl9RQS18FYerSwGUVfycSDgkGCZCx-H0JEjP0AikIqSQZbC1VyrzOwh_McihcDAUSKyhSsWcl-KTFfCjb7B6fEsgVz9_4p1BswetQb6pPEunMy6u-gGEZzrwqtz2RE05TVz5QZ4T6a7RrWEYy3FS7g==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CytomX Therapeutics, Inc.<\/strong><br \/>\n        <br \/>CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics localized to the tumor microenvironment. By pioneering a novel class of conditionally activated biologics, powered by its Probody\u00ae technology platform, CytomX\u2019s goal is to transcend the limits of current cancer treatments. CytomX\u2019s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (\u201cADCs\u201d), T-cell engaging bispecific antibodies (\u201cTCBs\u201d), and immune modulators such as cytokines and checkpoint inhibitors (\u201cCPIs\u201d). CX-2029 is an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD71. CytomX\u2019s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors and CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZbV-is7xQWIp2HUqNgOxQ1-TLKOQhcKBwaqX9_vF6JiQq2xxsIArBbA07E9HglmLm2J7eYv42AQSE7N6OUsRUQ==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/cytomx.com\/<\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t3RYNYdhuXLT3wO6mjcHasANBj77AjZOWpQbRjcfs0COAPHBwjSPlV7HjIFHg7vo2hdt_eniD7ZBWACV5iMd0vgeMBpAaCuFm4fQQm6paBzBnGIvRZDPLW1tS-erHMnG\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0EV8CN_w0DNYY82VvGzAMe9ZsmFdLJU6CHklOPOeuJL-aJLU2-cWcWPrCupJiOBnqIhXTWjExQbqeh_P1rpKyCa4IgrSAglmfD3ky_2ok7Q=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.<\/p>\n<p align=\"justify\">\n        <strong>CytomX Contact:<\/strong><br \/>\n        <br \/>Chris Ogden<br \/>SVP, Finance and Accounting <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=79yZ_HJcvkN5Bc4BBHb7ekEBh2AAK-BXszmx0iKdeDXvg509CDFuE8Llolh2WwA6-QLzS1wcPj-18rVNL0iElg==\" rel=\"nofollow noopener\" target=\"_blank\">cogden@cytomx.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wLNSjxiEhDJHGmLk7pUAtiDoD06ROdb6QaLQ147u3skTRKqGQ3FQQF8dtxxkaEmV\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>(317) 767-4764<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Stern Investor Relations<br \/>Stephanie Ascher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ch49XjLQCLLIr41q6X0h18GIeee0scDcYqkV7psMksPR2jmlSrFCnj9b1p7Zp21RCkT1WQzdGuZ7EZ4z-E7gD6jp4-XD0RQwZKgAObo3ReZ4mBd42YkG7_SfFEa03Mf6\" rel=\"nofollow noopener\" target=\"_blank\">stephanie.ascher@sternir.com<\/a><br \/>212-362-1200<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGE2Y2RkMjgtYTRjNy00ODlmLTg2ZjUtNjZhYjg4ZDI4NDRiLTEwMzE3OTk=\/tiny\/CytomX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on\u00a0Tuesday, May 9, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s website. About\u00a0CytomX Therapeutics, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753183","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on\u00a0Tuesday, May 9, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s website. About\u00a0CytomX Therapeutics, &hellip; Continue reading &quot;CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T20:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023\",\"datePublished\":\"2023-05-01T20:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\",\"name\":\"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\",\"datePublished\":\"2023-05-01T20:13:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on\u00a0Tuesday, May 9, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s website. About\u00a0CytomX Therapeutics, &hellip; Continue reading \"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T20:13:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023","datePublished":"2023-05-01T20:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","name":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=","datePublished":"2023-05-01T20:13:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTE1MyM1NTY1MjI4IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753183"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753183\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}